Home Page: JTO Clinical and Research Reports
JTO Clinical and Research Reports
JTO & JTO CRR (@JTOonline) / Twitter
JTO & JTO CRR (@JTOonline) / Twitter
JTO & JTO CRR on Twitter: "Our Editor-in-Chief, Dr. Alex Adjei, addresses the @IASLC #WCLC19 General Assembly, describing the incredible growth of the JTO (including a new impact factor of 12.460) and
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China - ScienceDirect
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -
The JTO Clinicial and Research Reports (JTOCRR) - YouTube
Home Page: JTO Clinical and Research Reports
Journals | IASLC
PDF) A Systematic Review and Meta-analysis of Clinical Characteristics and Outcomes in Lung Cancer Patients with COVID-19
Home Page: JTO Clinical and Research Reports
JTO Clinical and Research Reports
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China - ScienceDirect
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China - ScienceDirect
Home Page: JTO Clinical and Research Reports
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer - Journal of Thoracic
Home Page: JTO Clinical and Research Reports
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation -
Journal of Clinical Research and Reports| Auctores
Journal of Thoracic Oncology | Elsevier Pharma Solutions
